Literature DB >> 8746922

Subcutaneous injection of an analog of neuropeptide FF prevents naloxone-precipitated morphine abstinence syndrome.

D H Malin1, J R Lake, D A Smith, J A Jones, J Morel, A E Claunch, P A Stevens, K Payza, K K Ho, J Liu.   

Abstract

There is evidence that neuropeptide FF (NPFF) has antiopiate activity and may play a role in opiate dependence and subsequent abstinence syndrome. A fragment of NPFF was modified at the C-terminal in an effort to convert it to an NPFF antagonist. It was also dansylated at the N-terminal in an effort to render it more lipophilic and increase its penetration of the blood-brain barrier. Third ventricle administration of the resulting compound, dansyl-PQRamide (0.75 microgram and 1 microgram), dose-dependently antagonized the quasi-morphine abstinence activity of NPFF (10 micrograms) in opiate-naive rats. Subcutaneous injection of dansyl-PQRamide (13 mg/kg) in chronically morphine-infused rats attenuated opiate dependence as indicated by prevention of naloxone-precipitated abstinence syndrome. Dansyl-PQRamide displaced radiolabelled ligand from NPFF receptors in a concentration-dependent manner with a Ki of 13 microM, and had a half-life over 300 times longer than NPFF under aminopeptidase digestion.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8746922     DOI: 10.1016/0376-8716(95)01178-1

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  2 in total

1.  Involvement of neuropeptide FF receptors in neuroadaptive responses to acute and chronic opiate treatments.

Authors:  K Elhabazi; J M Trigo; C Mollereau; L Moulédous; J-M Zajac; F Bihel; M Schmitt; J J Bourguignon; H Meziane; B Petit-demoulière; F Bockel; R Maldonado; F Simonin
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

2.  Role of neuropeptide FF in central cardiovascular and neuroendocrine regulation.

Authors:  Jack H Jhamandas; Valeri Goncharuk
Journal:  Front Endocrinol (Lausanne)       Date:  2013-02-07       Impact factor: 5.555

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.